Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

MOUNTAIN VIEW, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the third quarter and nine months ended September 30, 2010.

Third Quarter HighlightsOn September 21, 2010, we announced top-line results from a two-year study of Qnexa which showed significant and sustained weight loss of greater than 10% over two years. Patients taking top- and mid-dose Qnexa achieved and maintained weight loss over two years of 11.4% and 10.4% of their initial body weight, respectively, as compared to placebo-treated patients with 2.5% weight loss (ITT-LOCF, p<0.0001). The findings come from the SEQUEL study (OB-305), a 52-week extension study for a subset of patients who completed the previously reported 56-week CONQUER study. The total study period was 108 weeks. SEQUEL included 675 obese or overweight patients, all of whom had two or more weight related co-morbidities, and an average baseline BMI of 36.1. Consistent with the first year experience, QNEXA therapy was well tolerated, with no new or unexpected adverse events. The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia.

On October 1, 2010, we entered into a definitive asset purchase agreement with Meda to transfer our rights and assets related to MUSE, transurethral alprostadil, for the treatment of erectile dysfunction (ED).The acquisition price was $23.5 million, which includes an upfront cash payment of $22 million. The Company is eligible to receive a one-time milestone payment of $1.5 million based on future sales of MUSE. Meda has been our European distributor of MUSE since 2002. The assets sold include the United States and foreign MUSE patents, existing inventory and the manufacturing fa
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Compare Genous vs. Drug-Eluting and Bare ... ... in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R ... April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and director ...
... 16 Protocol Driven Healthcare,Inc. (PDHI) today ... Hallmark Insights to provide fully integrated incentive ... ConXus health improvement platform. ConXus Rewards ... points earned by participants completing activities within ...
Cached Medicine Technology:Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
(Date:8/31/2014)... August 31, 2014 Healthy Grid ... cavities. Loloz lollipops will use herbs to fight ... hard candies will also fight bacteria while stimulating saliva production. ... together,” said Andrew Clapp of Healthy Grid. “Even though personal ... can always use a little more prevention. Cavities are painful ...
(Date:8/31/2014)... CO (PRWEB) August 31, 2014 ... released award winning, “Simplicity & Sophistication: Short Stories ... written and narrated by Dr. James W. Jackson author, ... Sophistication,” Dr. Jackson compresses his vast volume ... four decades into over 150 countries on behalf of ...
(Date:8/31/2014)... 2014: Renal denervation seems to be more successful at ... it includes accessory renal arteries, according to research presented ... Germany. , Dr Schmiedel said: "More than one billion ... as blood pressure (BP) greater than 140/90 mmHg. Up ... and are unable to reduce BP below 140/90 mmHg ...
(Date:8/30/2014)... Sunday 31 August 2014: Local anaesthetic is as safe ... general anaesthetic, according to results of the FRANCE 2 ... Chopard from France. , Dr Chopard said: "Numerous studies ... for patients with severe symptomatic aortic stenosis who are ... aortic valve replacement. The number of TAVI procedures in ...
(Date:8/30/2014)... Not only is USHEALTH Advisors now on pace ... its highest level of late-summer sales, including a new company ... to set a new record in 2014,” stated USHEALTH Advisors ... in both weekly annualized volume and the amount of writing ... August, we saw even more of our agents enjoying tremendous ...
Breaking Medicine News(10 mins):Health News:Healthy Grid: Fight Cavities With Sweet Treats 2Health News:Healthy Grid: Fight Cavities With Sweet Treats 3Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2
... For his dedication to advancing the diversity of doctoral-level ... the American Association for the Advancement of Science (AAAS) ... DeSimonewho serves as both the Chancellor,s Eminent Professor of ... Hill (UNC), and as the William R. Kenan, Jr. ...
... (BWH) was selected by the Centers for Medicare & ... a demonstration project that promotes appropriate utilization of advanced ... was selected as a convener under the Medical Imaging ... Medical Center-Physician Hospital Organization; University of Wisconsin Hospital Foundation, ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Feb. 16 ... state-of-the-nation,s health report and the news is mixed, with life ... On the positive side, life expectancy was up slightly ... beginning of the decade. And while women are still ...
... the unpredictable economy, nearly three-quarters (73%) of New Jersey ... globally is important to jobs and incomes in the ... Research!America. The poll data will be released today at ... research and development (R&D) experts and New Jersey business, ...
... (HealthDay News) -- Americans living in parts of Appalachia ... active in their free time, according to federal government ... least likely to be physically active during leisure time ... inactivity rates are 29.2 percent or greater for more ...
... , WEDNESDAY, Feb. 16 (HealthDay News) -- Many American parents ... and cold medicines to their kids despite U.S. Food and ... In response to research linking over-the-counter (or OTC) cough and ... ages 2 years and younger, the FDA said in 2008 ...
Cached Medicine News:Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 3Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 4Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 2Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 3Health News:America's Health a Mixed Bag: Report 2Health News:America's Health a Mixed Bag: Report 3Health News:Most New Jersey residents see global health as critical to state's economy 2Health News:Most New Jersey residents see global health as critical to state's economy 3Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Parents Still Giving Cough, Cold Meds to Kids Under 2: Poll 2
... A product you can trust its ... perform retinal, cataract, and glaucoma therapy ... III Combi is the optimal system ... and combined iridotomy. The push of ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... is a top quality Carl Zeiss Meditec ... vision defects even safer, more patient-friendly and ... work platform are oriented towards increasing efficiency, ... recovery of vision. Key factors here are ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: